DAMON BIOTECH WILL EXPAND CLINICAL TRIALS OF PATIENT-SPECIFIC MONOCLONAL
DAMON BIOTECH WILL EXPAND CLINICAL TRIALS OF PATIENT-SPECIFIC MONOCLONAL antibodies for the treatment of B-cell lymphomas begun by Stanford-based researchers, the company announced in a press release Oct. 17. Clinical trials with the individualized monoclonals will be expanded to include several hundred patients in several university centers, the company said. Work with the treatment will be layered onto clinical work already underway by Damon with monoclonals for B-cell lymphoma involving some 20 patients at the Natl. Cancer Institute. Damon announced that it had purchased a controlling interest in Biotherapy Systems, founded recently by Stanford-based oncologists Ronald Levy, MD, and Richard Miller, MD, and by Barnet Adelman, a former VP of United Technologies. Levy first began clinical work with the patient-specific monoclonal antibodies for the treatment of B-cell lymphoma in 1981. The oncologists expect to publish updated results of their work shortly. Damon said that the clinical know-how provided by Biotherapy Systems will be linked to Damon's manufacturing technology to make available a sufficient quantity of the patient-specific antibodies for expanded clinical testing. The Stanford group will be involved in enrolling patients and producing the specific cell lines. Damon will then use the cell lines to manufacture the antibodies, and return them for patient treatment.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth